Arrowhead's plozasiran (ARO-APOC3) has delivered highly promising clinical data in severe hypertriglyceridemia (sHTG), with median triglyceride reductions of about 80% and deep suppression of cardiovascular‑risk lipids such as remnant cholesterol and non‑HDL‑C across long‑term and Phase 3 studies. In SHASTA‑3 and SHASTA‑4, 25 mg plozasiran given every three months reduced median triglycerides by 79–81% at 12 months versus placebo and significantly cut the rate of acute pancreatitis events, especially in the highest‑risk sHTG patients. Long‑term data from a two‑year open‑label extension show sustained effects, with 96% of sHTG patients reaching triglycerides below 500 mg/dL and a clean safety profile, positioning Arrowhead as a strong competitor to Ionis in the hypertriglyceridemia space.
Sources:
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy ...
Arrowhead Presents New Clinical Data on ... - Nasdaq
Arrowhead on target in lipid disorder as it shoots into phase 3 behind Ionis
Arrowhead (ARWR) Q2 2026 Earnings Transcript | The Motley Fool
Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians
Arrowhead reports initial data for cardiometabolic candidates
Biotech rivals clash as Arrowhead sues Ionis over RNA-based ...
Arrowhead RNAi med lowers triglycerides in phase 3 - Fierce Biotech
Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
Arrowhead Pharmaceuticals Presents New Phase 2 Data ...
With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis - MedCity News